Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes

Clinics

Volumn 67, Issue 3, 2012, Pages 219-223

  Oliveira, Lucivalda Pereira Magalhães ^a   de Jesus, Rosangela P ^a   Boulhosa, Ramona S S B ^a   Mendes, Carlos Mauricio C ^a   Lyra, Andre Castro ^a,b   Lyra, Luiz Guilherme C ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b HOSPITAL SÃO RAFAEL   (Brazil)

Author keywords

Chronic hepatitis C; Genotype 1; Insulin resistance; Metabolic syndrome; Overweight

Indexed keywords

EID: 84859401369     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(03)03     Document Type: Article

References (28)

1. Sabahi A. Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J. 2009;6:117.
2. Ferreira C, Silveira T. Hepatites virais: aspectos da epidemiologia e da prevenção. Rev Bras Epidemiol. 2004;7(4):473-487.
3. Ministério daSaúde. Casos confirmados de Hepatite C. Brasil, Grandes Regiões e Unidades Federadas. 2007. Available at: http://portal.saudegov.br/portal/arquivos/pdf/casos_hepatite_c.pdf (accessed December 2010).
4. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003;34(1):1-10.
5. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001;35(2):297-306.
6. World Health Organization. Initiative for Vaccine Research (IVR): Hepatitis C, 2008. 2010. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html (accessed December 2010).
7. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15(13):1537-1547.
8. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27-38.
9. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410-1415.
10. World Health Organization. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. Geneva: World Health Organization (WHO); 2008.
11. Lohman TG. Advances in body composition assessment. Current issues in exercise science series. Champaing: Human Kinetics; 1992.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
13. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986;292(6512):13-15.
14. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
15. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ. 1995;311(7017):1401-1405.
16. R DEVELOPMENT CORE TEAM. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2010. Internet: http://www.R-project.org (accessed October 2010).
17. Huang JF, Chuang WL, Yu ML, Yu SH, Huang CF, Huang CI, et al. Hepatitis C virus infection and metabolic syndrome--a community based study in an endemic area of Taiwan. Kaohsiung J Med Sci. 2009;25(6):299-305.
18. Serste T, Nkuize M, Moucari R, Van GM, Reynders M, Scheen R, et al. Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity. Liver Int. 2010;30(8):1131-1136.
19. Hsieh MH, Ho CK, Hou NJ, Hsieh MY, Lin WY, Yang JF, et al. Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. Int J Obes (Lond). 2009;33(11):1309-1317.
20. Grigorescu M, Radu C, Crisan D, Grigorescu MD, Serban A, Neculoiu D, et al. Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2008;17(2):147-154.
21. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut. 2005;54(7):903-906.
22. Abdel-Azziz MY, Zalata KR, El-Bendary MM. Insulin resistance and liver fibrosis progression in patients with chronic hepatitis C virus infection. Arab Journal of Gastroenterology. 2010;11(1):30-34.
23. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54(7):1003-1008.
24. Mizuta T, Kawaguchi Y, Eguchi Y, Takahashi H, Ario K, Akiyama T, et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci. 2010;55(1):183-189.
25. Romero-Gomez M, Del M, V, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636-641.
26. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(1):127-133.
27. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res. 2005;37(4):246-251.
28. Hanouneh IA, Feldstein AE, Lopez R, Yerian L, Pillai A, Zein CO, et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008;6(5):584-589.